

Medical Devices Regulation

Technical Documentation Submissions Lessons Learnt

Kevin Madden & Chris Wylie Regulatory Services (Medical Devices), BSI

5th May 2021



Copyright © 2021 BSI. All rights reserved

Your Speakers Today

Kevin Madden



Technical Team Manager, Orthopaedic & Dental Devices BSI **Chris Wylie**



Global Head, Orthopaedic & Dental Devices BSI



The most common reasons for delays in technical documentation reviews are:


- **Incomplete Submissions** all the information needed for the review not provided
- **Poor structuring of Technical Documentation** information present but difficult to locate.







- 1. MDR Technical Documentation Review Process
- 2. Common Gaps/Questions from MDR Technical Reviews
- 3. Improving Technical Documentation Submissions
- 4. Questions





4

How confident are you that you understand the MDR Requirements in relation to Technical Documentation Submissions?

- a) Very Confident
- b) Slightly Confident
- c) Enough to Survive
- d) Don't have a clue!





MDR Technical Documentation Review Process





MDR Annex II - Technical Documentation (TD)

L 117/108

EN

Official Journal of the European Union


5.5.2017

ANNEX II

TECHNICAL DOCUMENTATION

The technical documentation and, if applicable, the summary thereof to be drawn up by the manufacturer shall be presented in a clear, organised, readily searchable and unambiguous manner and shall include in particular the elements listed in this Annex.

- 1. DEVICE DESCRIPTION AND SPECIFICATION, INCLUDING VARIANTS AND ACCESSORIES
- 2. INFORMATION TO BE SUPPLIED BY THE MANUFACTURER
- 3. DESIGN AND MANUFACTURING INFORMATION
- 4. GENERAL SAFETY AND PERFORMANCE REQUIREMENTS
- 5. BENEFIT-RISK ANALYSIS AND RISK MANAGEMENT
- 6. PRODUCT VERIFICATION AND VALIDATION



7

Annex II Technical Documentation

- 1. Device Description
- 2. Information to be supplied by the manufacturer
- 3. Design and Manufacturing Information
- 4. General Safety and Performance Requirements
- 5. Benefit-Risk analysis and risk management
- 6. Product verification and validation

Annex III Technical Documentation on Post-Market Surveillance

- Post-Market Surveillance (PMS)
 Plan
- Post-Market Clinical Follow-Up (PMCF) Plan
- Periodic Safety Update Report (PSUR)

Annex XIV – Clinical Evaluation and Post-Market Clinical Follow-Up



MDR Technical Documentation – Best Practice

- BSI provides this guide.
- A complete and well-organised technical documentation file decreases time and cost of the review.
- Searchable, bookmarked PDF files
- The technical documentation should be available in full in accordance with Annex II.

BSI Transitions Medical Devices Regulation		MGH Departmentation Submeasure - Revision 2, May 2020
	1111 🔬 🕒	Contents
		Submission and Technical Document Cover letter. Z. The Technical Documentation Z.3 Authorisations for the work to be co
		Submission Method Document Format 4.1 Language 4.2 Electronic File Format 4.2.1 Format and file size limits 4.2.2 Optical Character Recognition (search 4.2.3 Bookmarks 4.2.4 Signatures 5 Submission process 6 Additional topics to consider when p
MDR Document Submissions	ation	submission 6.1 Manufacturer personnel support 6.2 Document availability 6.3 Languages 6.4 Certificate scope 6.5 Subcontractors & Suppliers 6.6 Accessories
Best Practices Guidelines	Revised	6.7 Novelty
	May 2020	
bsi.	making excellence a habit."	bsi.

https://www.bsigroup.com/globalassets/meddev/localfiles/de-de/documents/bsi-md-mdr-best-practice-documentation-submissions-en-gb.pdf




making excellence a habit

Freque 2 lot 41.

ng Technical Documentatio

echnical Documentatio

MDR Technical Documentation Completeness Check



bsi.

MDF5007

MDR Technical Documentation Completeness Check Revision No 0 (May 2020)

3 Supplemental Guidance

Guidance is available from BSI on the best practices in relation to preparation of Technical Documentation from the following link: https://www.bsigroup.com/globalassets/meddev/localfiles/en-gb/documents/bsimd-mdr-best-practice-documentation-submissions-en-gb.pdf

4 Technical Documentation Completeness Checklist

4.1 Client Details

Manufacturer	
Single Registration Number (SRN)	
Name of the device(s) the Technical Documentation is associated with	
Basic UDI-DIs covered	
Impacted BSI certificates (if known)	
Date of submission to BSI	

4.2 Technical Documentation Checklist

Section Title	Item	Location of the requested information; Mark as "N/A" if not applicable and provide a brief justification	BSI Completeness Check (To be completed by BSI)
Overview	Cover letter		TYES NO
	MDF4900 – BSI Change Notification Form		□YES □NO □N/A with justification
	Document index		TYES NO
	Top level (or summary) Technical Documentation (STED) file		□YES □NO □N/A with justification
BSI Comments - Overview		•	

...making excellence a habit.

The contents of this document are confidential to BSI Group The definitive version of this document is only available through the BSI BMS

Page 1 of 10

.making excellence a habit."

Page 4 of 21

The contents of this document are confidential to BSI Group The definitive version of this document is only available through the BSI BMS



MDF5007

MDR Technical Documentation Completeness Check

Revision No 0 (May 2020)

Section Title	Item	Location of the requested information; Mark as "N/A" if not applicable and provide a brief justification	BSI Completenes Check (To be completed by BSI)
1.1 Device Description	1.1.1 General description including product or trade names, principles of operation, mode of action etc		□YES □NO □N/A with justification
	1.1.2 Accessories included		□YES □NO □N/A with justification
	1.1.3 Accessories not included but necessary for use		□YES □NO □N/A with justification
1.2 Intended Purpose and Intended Users	1.2.1 Intended purpose including any clinical claims		□YES □NO □N/A with justification
	1.2.2 Intended users		□YES □NO □N/A with justification
1.3 Basic UDI-DI & EMDN code	1.3.1 Basic UDI-DI and any other relevant UDI related information		□YES □NO □N/A with justification
	1.3.2 EMDN code (previously referred to as CND code)		□YES □NO □N/A with justification
1.4 Devices covered by technical documentation	1.4.1 List of type, sizes, configurations, variants etc including catalogue numbers covered by the submitted technical documentation		□YES □NO □N/A with justification
1.5 Classification	1.5.1 Classification of the device including all the applicable rules and relevant rationales		□YES □NO □N/A with justification
1.6 Materials	1.6.1 Description and identification of key materials incorporated into the device		□YES □NO □N/A with justification

.making excellence a habit.

The contents of this document are confidential to BSI Group The definitive version of this document is only available through the BSI BMS

Page 5 of 21



Copyright © 2021 BSI. All rights reserved

Make a full and thorough MDR submission

• Completeness Check prior to formal TD review


Section Title	Item	Location of the requested information; Mark as "N/A" if not applicable and provide a brief justification	BSI Completeness Check (To be completed by BSI)
3.4 Sites involved in design and manufacturing activities	3.4.1 Legal Manufacturer (as per EUDAMED registration)	Section 1.2 of ABC-XYZ-035 (Page 5)	⊠YES □NO □N/A with justification
	3.4.2 European Representatives	Section 1.3 of ABC-XYZ-035 (page 5)	⊠YES □NO □N/A with justification
	3.4.3 Site with Design responsibility	Section 4.3 of ABC-XYZ-035 (page 16)	YES □NO □N/A with justification
	3.4.4 Sterilisation subcontractors	Section 4.3 of ABC-XYZ-035 (Page 17)	YES □NO □N/A with justification
	3.4.5 Other critical subcontractors and crucial suppliers relevant to the	Section 4.3 of ABC-XYZ-035 (Page 17)	□YES ⊠NO □N/A with justification
	device(s) including any copies of certification held by such entities		No critical subcontractors listed
BSI Comments –	Inclusion of requested inforr	nation confirmed except <mark>no critical subco</mark>	ntractors listed.
Section 3		ther critical subcontractors and crucial su e copies of certification held by such enti	

".....We thought we would send you the top-level documents, and then follow up with more as you need them." - Manufacturer

11

MDR TD Review Limitations – some specifics

- 3 rounds of questions
- MDR Annex VII section 4.5.1 specify rationale for time limits for completion of conformity assessment activities
- BSI rationale based on rounds of questions rather than a time limit



Copyright © 2021 BSI. All rights reserved

MDR TD Assessment – Timing and Limitations



Completeness Check

Three rounds

Ensuring all documentation is present and generally complete at a glance – not a detailed technical assessment

BSI will be required to reject applications if gaps cannot be addressed in three rounds of questions

In those cases, Manufacturer will be required to resubmit an amended application

Technical Documentation Assessment – MDCG 2019-13

5.1. Depth of the assessment

The depth and extent of the technical documentation assessment of Class IIa / IIb and Class B / Class C devices will be the same as the depth of assessment carried out for Class III and Class IIb implantable and Class D devices.

This means that the technical documentation of a device shall be assessed against all General Safety and Performance Requirements (Annex I) and requirements of Annex II and III. Records of the assessment shall be prepared which allow a third party to understand the functionality of the device and all aspects of the assessment including judgements made by the assessor.

It should be taken into account that every device (i.e. Basic UDI-DI) might include different variants, models or sizes. In that case, the review of the technical documentation will also include the assessment of how the differences among these have been addressed in the technical documentation and whether all of them are in line with the relevant requirements.

Depth and extent of TD assessment to be same irrespective of device classification

TD assessment durations determined by device type (MDA/MDN codes) and complexity rather than device classification;

• Characteristics such as presence of animal tissues, nanomaterials (MDS codes) increase the assessment durations

14

It is important to follow the EU Guidance Documents because...

- relating to the sampling of devices, verify that the manufactured device is in conformity with the technical documentation; such requirements shall define the relevant sampling criteria and testing procedure prior to sampling,
- evaluate and verify a manufacturer's compliance with relevant Annexes.

The notified body shall, where relevant, take into consideration available CS, guidance and best practice documents and harmonised standards, even if the manufacturer does not claim to be in compliance.

MDR, IVDR - Annex VII Section 4.5.1

EU MDCG Guidance Documents

https://ec.europa.eu/health/md_sector/new_regulations/guidance_en

Me

Rev.1 🔑 즢

<---)

MDCG 2018-1 v3 🔑

Topic Headings Include:

- UDI
- EUDAMED •
- European Medical Device Nomenclature (EMDN) •
- Notified Bodies •
- Clinical Investigation and Evaluation •
- New Technologies •
- Other Topics •
- Commission guidance Documents •
- Other Guidance Documents •

ledical Device	s - Secto	or				
All topics	Overview	Current Directives	New Regulations			
						2
Guidance - N	/DCG e	endorsed do	ocuments			
The European Commiss regulations.	ion provides a	range of guidance of	locuments to assist	stakeholders in impleme	enting the medical devic	es
0, 00		· · · ·		on group (MDCG) in acco evant provisions of the reg	rdance with Article 105 of julations within the EU.	
MDCG work in Ongoing guidance docum						
⇒ UDI						
Reference	Title				Publication	
MDCG 2018-3	Guidance	on UDI for systems and	h procedure packs		June 2020	

Guidance on UDI for systems and procedure packs

Guidance on basic UDI-DI and changes to UDI-DI

June 2020

March 2020

MDCG Guidances, EUDAMED

https://ec.europa.eu/health/md_sector/new_regulations/guidance_en https://ec.europa.eu/health/md_eudamed/overview_en

and the second sec	through a staffs of Beglause germanic is sense employing	+ Clinical Investiga	tion and evaluation	
Agely non-trading potent Repulsion Tabler 17 Junio	n muuremin, adapted by the realized device contribution group (H in the abactive of sensitivity collision application of the reference process	Reference -	1984	Patricial
MDCG work in p			Chical available suscentry report includes	Arin 2228
+ UDI		NETTIN 2000-19-1 4		Mag 2000 Mag 2000
Patherana	Pilar	1000 2004 Ju	Guidance on PHCP and alloc react program.	April 2028
Real Article	Sufferences (2016) autores exceptionlare packs:	Neurosci da como de presiona de la como de l	Dubling of PVC7 participants	April 2008
MEASURE FOR FOR ALL	And an a second state of the second state of the	NEWS YORK AND	Colores in a direct drive events to leave terms	April 2000
3000		vierza znate a jij 🖂	factorie of street and story lightware	Sec. 2528
MOCE BIRALAE	1000 pality principles for leaving willing sizes, and con-	ARROY DOWN	Summer of addition of strends by the same	August 2018
Moos and Al	Conterns or applicators of LD constantions and of products on system 105, 105 and 1010 of Degistration 2020117	· New technologie		
MODE BITE Z JE	Found Direction does never the Company of malors	Salesca.	100	Participan -
ucci ana cji	Deli-duesciouripture, and factorie of the UD case another factories for a presentate particulate particulate	antice and a Million	Destance as about promotion (PDP). Performance measures promit	1 March 2020
upon prink (F.	and the second discovery of the second second	anizi zna in 🏭	Ocalitation Announcement and a Reaction (REEDOTTY)) and Regulation (REEDOTTM)	(1414a - 2716 -
Martin anne Alf	Cheffonderer of UD restort reparabilities in strates to active th	1000 200 H == 1.8	Sections in colorana is to realize incom-	Delation 1278
Accesses the	Proylegel Gradination regardly language latest associated I/O stateme	+ Other topics		
EUDAMED		Bellevine.	Tota	Palitates
Patternice	70e	1000 000 a 200	Regardley requirements for constants and reason and an approximate	-Aur+ 2020
MOOT THE 11 JE	MECE Name Page or he use of the EUD/ACE and report models and of the Engle Registration Particle (2014) in the Me Easter	and the second s	integration of artists (1923)	444.000
MOCE STRAIN (CO)	Trains to agente el livia das menos in D.6/403	WOOD 200-Dree 1 Pt	Case I mendionel provinces a har Adam 122 (Lara H-1)8081	Marin 2000
MICE 279 8.40 (11)	Registration of Ingels; desires in EUXAGED	4206 20-94-0 P	Colorest doubert installing on the automory of Abile 10.	
Formers Medica	I Device Nomenclature (EMDN)	()	Page 2000 (BU) 2227/748 or marked amount	Among plant
The Open Provide State	Contract Internet in the second	4000 200-0 mm1.F	Guilletia mini fermandadores af stata (medial destas)	Dearmy 2010
To DOM: To come	neer al anno 1,0000 (C) Teolographical growt ar anno (C)	1000 (000 - 100 (000	Subtrave or artists III of this method taxine, september (WOR) and m vibio depress device regulation (NOR) or a securit responsible for responses membrane (PRPR).	June 2218
Notified bodies		- Commission guis	lance documents	
Paterioria.	Title-	10m		Fabloane
Approximation (a) (a)	Qualitation for real-first localizes on the user of M2000P tools require a manifest of surveylence marks content and online for Markov Decision			Add Highling
	Happenine (MDPD) in the Dispression resolute devices Republica-		ingenie and personal protective exceptions per balland, by planet or	Hay 2021
Bernard B	Decisions on mensional processes for consolutions of autorises reconstrained by a substance which range in consistent a resolution p which has define any lines to that of the denses, so well as or does		ermand and used - also in the 2000 Hit series. All Collinsors	Autor 2020
ANCO DOD OF AD	rearchitecture area TE interpretes which before Sections on the removal of designation and manipulation of well- and Sections (CONSTER) and INCOME to be performed to a	Georges or matter said reading inclusion in the CD	na artis equatara maline assus ara ir sta dagranta 10.0 assas R ()	Agril 2020
Model and The	sense presented to discuss and its spectra to be suffered to a	Control is associated in	ministration for 122 proving and 122 provide products to be used by a	Auri 2020

Medical Devices - EUDAMED

Overview

O All topics

Overview

EUDAVED as the IT system developed by the European Commission to imperiam Registation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in othe diagnosis medical devices.

The new Republicity curtain important improvements including a much larger EUDAMED database than the one that currently works under the Medical Devices Directives (Euclament2).

EUDAMED will reprove transparency and coordinators of information regarding medical devices available on the EU market.

The system will be multipurpose, if will hardose as a registration system, a collaborative system, a natilization system and a documination system (open to be public) and will be interoperable.

EUDAMED is phachared around 6 interconnected modules and a public website

- Actors registration
- UDI/Devices regariation
- Numbed Rodex and Certificater
 Circal Investigations and performance studies
- · Vigilance and post-market surveillance
- · Market Surrediance

What is the state of play of the implementation of EUDAMED?

- . The development and implementation of EUE/AMED is a high priority for the Commission
- The Continuum, in agreement with the Medical Device Coordination Onlap (MDCO), is gaing its make available the different modules on a gradual basis as searces they are functional.
- The module on Actor registration will be the first module hade available. Deployment of the module is parameter 2029.
 The todaue on VOINDevice registration (second module) and the roodse on Certificates and Notified Bodies Other nodse) will be the solution (second module) and the roodse will be functioned by the VOINDEVICE interview.

Functional specifications

The Exclament functional specifications (v4.1) [2] (····) have here public since 7 February 2019. These functional specifications regist be subject to possible changes as some increases with under declament.

MDR/IVDR UDI and device

Overview of the MDH SIDE and device data sets (2) (1) and tVDH SIDE and device data sets (2) (1) to provide for their negativation in EUDAMED

EUDAMED LIDI device data dictionary 🛄 🔄 This document clarifies the data that you should provide to EUDAMED for the UDI device registration module



...making excellence a habit."

Get notified of updates to EU Guidance Documents

https://ec.europa.eu/health/md_sector/overview_en

Newsletter

Subscribe to the Medical Devices newsletter



Have you already submitted a file for MDR technical documentation review to your Notified Body ?

a) Yes

b) No, but ready to submit

c) No, we're not ready yet





MDR Technical Documentation Lessons Learned





Technical Documentation – Overall Feedback

- Generally, new MDR requirements are being clearly addressed
- Some areas continue to evolve with guidance being published and further experience being gained
- "Legacy" device challenges
 - Stand-alone new application file required; not "gap analysis to MDR"
 - Clear organization of files and data
 - Large numbers of reports with no explanation or map will slow review time
 - Consider testing map or summary tables
 - Rationales for applicability of any leveraged tests
 - Justifications needed when historical testing performed does not meet current standards (e.g. ISO 10993 and others)



Technical Documentation – General Feedback

✓Know your audience – provide context and evidence

✓All relevant reports must be provided - it is not acceptable to reference or leverage tests from the same device or another device that were "previously reviewed by BSI under MDD" without providing these test protocols/reports

✓Avoid chain referencing

✓ Review file fully before submitting




What have you found most challenging when preparing your technical documentation for submission to your Notified Body?

- a) Biological Evaluation
- b) Clinical evaluation
- c) Design V&V
- d) Design and Manufacturing Information
- e) None of the above





Technical Documentation – Questions Raised



These are early trends and may change with time and more experience

...making excellence a habit."

bsi

For "Legacy" MDD Devices – Tell the Story



Devices with a long history under MDD may have a history of device changes and/or company acquisitions

While each change was likely reviewed individually under MDD, MDR is a new stand-alone application with no grandfathering and **all testing must be presented and explained clearly** If it is not clear what testing was performed on what version, or what other testing was leveraged / justified over time, please clearly outline this to avoid questions

긠

vhatPlease do not present aormed"stack" of designorverification/validationng wasreports with noifiedcontext or explanationclearly- this will increase thedreview time and cost

.....

字 A 子

Similarly - if it is **not clear which clinical data was obtained on what historic version of the device**, please clearly outline this and justify applicability (equivalence) if the device has changed

Refer to BSI Best Practice Guidelines for additional guidance

Design V & V – Some common gaps

A clear trace matrix between specifications and relevant reports / sections can reduce review time significantly

Design requirements not fully verified/validated Missing protocols, reports – provide all referenced in design input/output matrix

Unclear organization of tests for legacy devices

Unclear / hidden rationales for leveraged tests

Evidence of performance over lifetime of device not demonstrated Test acceptance criteria not met – No justifications for accepting results

Sample sizes, selection criteria and preparation unclear

& many more....

Many apply to packaging tests also

Copyright © 2021 BSI. All rights reserved

26


Design V&V Roadmap – Acme Catheter 2.0



Specification	Acceptance Criteria	Testing Protocol/Report	Sample Tested	Justification for Sample Tested	Location in TD
1.01 – Tensile Strer of Tip	ngth >5N	P/R2013-06 — New Tip Design t=0 P/R2013-08 — New Tip Design t=24	Acme Catheter 2.0	Same subject device under application	Appendix 83 t=0 Appendix 84 t=24
1.02 – Tensile Strer of Hub	ngth >8N	P/R2011-03 – Acme t=0 P/R2011-05 – Acme t=24	Acme Catheter 1.0	Hub same as current 2.0 version under application; specification not impacted by tip change to 2.0	Appendix 86 t=0 Appendix 87 t=24
1.03 – Liquid Leaka	ige No leaks at <30 psi	P/R2011-03 - Acme t=0 P/R2011-05 - Acme t=24	Acme Catheter 1.0	Shaft same as current 2.0 version under application; specification not impacted by tip change to 2.0	Appendix 86 t=0 Appendix 87 t=24
5.11 — Pouch Peel Strength	> 1N/in	P/R2009-02 – CathBot t=0 P/R2009-05 – CathBot t=36	CathBot RX	Pouch and tray design identical to Acme 2.0 and mass of CathBot worst case; same acceptance criteria and testing method; shelf life greater than subject device	Appendix 88 t=0 Appendix 89 t=36

acceptance criteria

bsi.



27

Application of Standards

- No standards are yet harmonized to 2017/745 (MDR)
- List of standards to be harmonized is published but this has not yet been completed
- The most current standards are therefore considered state of the art e.g. ISO 14971:2019
- Present a clear gap analysis if older version of standards used
 - For tests, address whether current standards are considered met, conclusion why additional testing was not required
 - Often seeing different versions in a "claimed standards" list compared to test reports, with no gap analysis or explanation – present this proactively
- MDCG 2021-5, Guidance on standardisation for medical devices, April 2021

Medical Devices Medical Device Coordination Group Document


MDCG 2021-5

MDCG 20	21-5
Guidance	on standardisation for medical devices
April 2021	

This document has been endorsed by the Medical Device Coordination Group (MDCG) established by Article 103 of Regulation (EU) 2017/745. The MDCG is composed of representatives of all Member States and a representative of the European Commission chairs it.

The document is not a European Commission document and it cannot be regarded as reflecting the official position of the European Commission. Any views expressed in this document are not legally binding and only the Court of Justice of the European Union can give binding interpretations of Union law.

Clearly present Annex I / GSPR Compliance





Biological Safety – Common Issues

No overall biocompatibility assessment of the current version of the device under application

- Test reports for each iterative change over the years, without an overall explanation / assessment of <u>current</u> device
- Make clear the relevance of each test and how the subject device was considered as a new application
- Do not submit every biocompatibility test in a DHF with no explanations
- Overall biological safety assessment by qualified individual/team

Context of tests not clear

- Rationales for any tests leveraged comparing device specifics
- Rationale for any device attributes that have changed over time
- Consideration of manufacturing processes & changes
- Details of sample preparation and extractions not sufficiently discussed
- Proactive gap assessment of revised standards

Other items

- Clear rationales for any tests not conducted/presented
- Chemical characterization testing (especially legacy devices)
 - Justification of test method(s) selected
- Organization: Tests not individually bookmarked and referenced
- No evidence that biological safety evaluation connects to risk management


GSPR 10.4.2 (CMR / ED Substances)

Please provide objective evidence How complete is the information supporting the statement that the on components and device contains no CMR, endocrine manufacturing aids that you disrupting substances, or obtained from your suppliers? phthalates? Common Questions Please clearly outline what CMR / What, if any, additional testing or ED substances have been analysis was performed by you as identified in the device and at the manufacturer? what concentration (w/w)?



Manufacturing & Process Validations

- It is required to include full manufacturing validations in MDR submissions (MDR Annex II, Section 3b)
 - (b) complete information and specifications, including the manufacturing processes and their validation, their adjuvants, the continuous monitoring and the final product testing. Data shall be fully included in the technical documentation;
- Protocols and reports of critical process validations are required, not just summary
- Overall summary or Master Validation plan is still helpful to understand overall strategy and process
 - Include pointers to all detailed supporting documents




- Clear link between PFMEAs, manufacturing processes, incoming inspections and inline tests etc. for completeness and control.
- Process validations: what was run, including justifications for tests conducted, sampling rationale, raw data, product range covered.



Inspection Information – why is BSI asking for this?

- Incoming, in-process and final inspection checks and the results (Annex VII 4.5.3)
- Common question "Why is this being requested outside the QMS audit?"
- MDR requires that the NB review this as part of the Annex IX technical documentation assessment (not only QMS audits)



Lifetime in Use

- Lifetime of the device should be defined by the manufacturer (GSPR 6)
- How is evidence of performance over lifetime demonstrated in testing and clinical use?
- Post-Market Surveillance & PMCF plans should be suited to gathering data through the device lifetime (Art. 83, Annex XIV)

• Special device types:

• Implants

- Article 18 (Implant card and information to be supplied to patient): Expected lifetime of the device and any necessary follow-up
- SSCP: Information about the expected lifetime of the device including data on implant survival rates

• Software

 Lifetime of the device may be determined by hardware, or other required software

Clinical Evaluation – Some Common Gaps

Equivalence not demonstrated	Incomplete Safety & Performance data with respect to all indications/claims	Clinical benefits and risks not clearly addressed	Clinical benefits not measurable
Safety and performance endpoints not clearly defined	Patient population not clearly defined	State of the art not clearly established	Missing or incomplete clinical development plans
	Competence of the CER authors/reviewers	& many more	



Article 18 (Implant Card and Info to be Supplied)

What Article 18 documentation should manufacturers submit?

1. Explanation/justification for the solutions adopted by the manufacturer to meet art. 18 requirements and MDCG guidance.

2. Implant card drawing (back and front) and sticker drawings (if applicable)

3. Implant card specification

Physical/mechanical and material/chemical specifications for card (and stickers if applicable)

- 4. Informative instructions leaflet (or justification for not providing)
- 5. Art. 18.1 (b-d) information

Patient information leaflet

•screen shots from patient information website, hyperlink to working website etc.

6. Usability validation protocols/reports

Improving Technical Documentation Submissions




TD Submissions - Remember to Include:

- Information to allow the design stages applied to the device to be understood (Annex II Section 3a)
- ✓ Design Specifications or Design Inputs, etc. (Needed for Annex II Section 3)
- ✓ All Process Validations and associated Validation Plan (Annex II Section 3b)
- ✓ Risk Management Plan (Annex I, GSPR 3a)
- ✓ Clinical Evaluation Plan as well as Clinical Evaluation Report (Annex II Section 6.1c)
- Device-specific PMS Plan (Annex III), and PMCF Plan (if applicable) including proactive elements (Annex XIV)
- ✓ Incoming, in-process and final inspection checks and the results (Annex VII 4.5.3)

New requirements compared to MDD/AIMDD or often missed

TD Submissions - Additional Topics To Consider:

- Manufacturer personnel support
- Document availability
- ✓ Languages
- ✓ Certificate scope
- Subcontractors and Suppliers
- Accessories
- ✓ Novelty



Improving TD submissions – Final Thoughts:

- ✓ Regulations and regulators are clear that MDR is a new stand-alone application
- Make the documentation a numbered, fully searchable, bookmarked PDF and easy for the reviewer to navigate. Know your audience – provide context and evidence – tell the story.
- Read the salient portions of the MDR and the associated MDCG guidance documents and address these to the best of your ability/understanding
- A complete and well-organised technical documentation file decreases the time and cost of the review.



BSI Medical Devices – Use Our Resources

https://www.bsigroup.com/en-GB/medical-devices/resources

Brochures, Guides and Documents



MDR guidance

MDD Best Practice Guidelines > MDR Best Practice Guidelines > MDR Mapping Guide > MedDev 2.7.1 Rev 4 changes > MDR Conformity Routes > MDR Readiness Review >

Webinars



MDR - What we know



Descripted the presentation


White Papers and Articles






Person responsible for regulatory compliance (PRRC) - MDR/IVDR Article 15 ANY THE PERFORMENT DESIGNATION AND A DESIGNATION OF THE APPROXIMATION AND A

regulareza propert + & Porsan Risperridik ha Regulareza Comptania (PRRC) - # their deprivation to ensure that the contactly is intertrap certain spatch: BU might presents.




Software as a medical device - A comparison of the EU's approach with the US's approach the internetional Mobilal Device Repliciture House OFORT Larrants accelerate

warnational medical literia regulative convergence. The suppl the MORT. and down a countral transmission while performing in complicity a market likener Regulation and it technics on investical decay GaPER. This paper printing a companyor of two SaMD is required to the UL and in the UL.



true is all deferred to e-stational track of devices and endered safetaats and only are the black about of these offices of their controls are necessary to store of a loss star a size of loss of the post-



The conduction is their all wood (pairson in terms of the word) have consumery and segments intervide activities that a rendral doubt insid-further tax lass. This seper discusses reported new improvements for one market and post-market utinated investigations when the Carnelian WOM.

Training Resources



Medical devices regulation (MDR)

Transition from MDD to MDR	1 day
Technical Documentation for CE - Marking	1 day
Requirements of MDR for CE - Marking	1 day
Implementing of MDR for CE- Marking	3 days

Medical Device Single Audit Program (MDSAP)	2 days
ISO 14971 Risk Management	1 day
Creating and Maintaining Technical Files	1 day
Post-market Surveillance and Vigilance	1 day
Clinical Evaluation for Medical Devices	1 day
Process Validation for the Medical Device Industry	1 day
Introduction to Medical Device Software	1 day




Linked in

Join and follow us on LinkedIn hare your knowledge. hallenges and news with Chers on LinkedIn



- 1. MDR Technical Documentation Review Process
- 2. Common Gaps or Questions from MDR Technical Reviews
- 3. Improving Technical Documentation Submissions
- 4. Questions

NCI



42



Questions?



Available medical devices training courses include:

CE marking training courses

- MDD to MDR Transition
- Requirements of the MDR for CE Marking
- Implementation of the MDR for CE Marking
- Introduction to Medical Device Software

Specialist training courses

- Post Market Surveillance and Vigilance under MDR and IVDR
- Technical documentation for the MDR
- Remote Auditing

Visit our website at **bsigroup.com/training** to find out more and book your place

Thank you for joining today

Kevin Madden



Technical Team Manager, Orthopaedic & Dental Devices BSI **Chris Wylie**



Global Head, Orthopaedic & Dental Devices BSI

